Download PDF
CC BY 4.0 · TH Open 2020; 04(02): e119-e126
DOI: 10.1055/s-0040-1713683
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Effectiveness and Safety of Apixaban for Treatment of Venous Thromboembolism in Daily Practice

Stephan V. Hendriks 
1   Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands
2   Department of Medicine, Haga Teaching Hospital, The Hague, The Netherlands
,
Frederikus A. Klok 
1   Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands
,
Wilhelmina J.E. Stenger
1   Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands
,
Albert T.A. Mairuhu
1   Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands
2   Department of Medicine, Haga Teaching Hospital, The Hague, The Netherlands
,
Jeroen Eikenboom
1   Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands
,
Jaap Fogteloo
3   Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands
,
Menno V. Huisman
1   Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands
› Author Affiliations Funding None.
Further Information

Publication History

24 March 2020

25 May 2020

Publication Date:
24 June 2020 (online)

Also available at
   Permissions and Reprints

Abstract

Introduction Phase 3 trials have shown comparable efficacy of direct oral anticoagulants (DOACs) and vitamin K antagonists in patients with acute venous thromboembolism (VTE), with less major bleeding events in patients randomized to DOAC treatment. With DOACs being increasingly used in clinical practice, evaluation of the DOACs in daily practice-based conditions is needed to confirm their safety and effectiveness. The aim of this study is to evaluate the effectiveness and safety of apixaban in VTE patients in daily practice.

Methods In this retrospective cohort study, consecutive patients diagnosed with VTE in two Dutch hospitals (Leiden University Medical Center, Leiden and Haga Teaching Hospital, The Hague) were identified based on administrative codes. We assessed recurrent VTE, major bleeding and mortality during a 3-month follow-up period in those treated with apixaban.

Results Of 671 consecutive VTE patients treated with apixaban, 371 presented with acute pulmonary embolism (PE) and 300 patients with deep-vein thrombosis. During 3 months treatment, 2 patients had a recurrent VTE (0.3%; 95% confidence interval [CI]: 0.08–1.1), 12 patients had major bleeding (1.8%; 95% CI: 1.0–3.2), and 11 patients died (1.6%; 95% CI: 0.9–2.9), of which one patient with recurrent PE and one because of a intracerebral bleeding.

Conclusion In this daily practice-based cohort, apixaban yielded a low incidence of recurrent VTE, comparable to the phase 3 AMPLIFY study patients. The incidence of major bleeding was higher than in the AMPLIFY-study patients, reflecting the importance of daily practice evaluation and the fact that results from phase III clinical studies cannot be directly extrapolated toward daily practice.

Keywords

apixaban - direct oral anticoagulants - safety - efficacy - venous thromboembolism

Essentials

• In VTE treatment, phase 3 studies have shown comparable efficacy of DOACs and VKA, with a better bleeding profile.


• Both efficacy and bleeding rates may be underestimated in phase 3 trials because patients at higher risk of bleeding are usually excluded.


• In this practice-based cohort, the incidence of major bleeding was higher than in the AMPLIFY study patients.


• Results from phase III clinical studies cannot be directly extrapolated toward daily practice.


Authors' Contributions

S.V.H. contributed to concept and design of the study, analyzed and interpreted the data, and drafted the manuscript. M.V.H. contributed to concept and design of the study, analyzed and interpreted the data, reviewed the manuscript, and provided important intellectual content. J.C.J.E. reviewed the manuscript and provided important intellectual content. J.F. reviewed the manuscript and provided important intellectual content. W.J.E.S. analyzed and interpreted the data and provided important intellectual content. A.T.A.M. reviewed the manuscript and provided important intellectual content. F.A.K. reviewed the manuscript, contributed to concept and design of the study, and analyzed and interpreted the data.


 

  • References

  • 1 Kearon C, Akl EA, Ornelas J. , et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149 (02) 315-352
    CrossrefPubMedSearch in Google Scholar
  • 2 Kirchhof P, Benussi S, Kotecha D. , et al; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37 (38) 2893-2962
    CrossrefPubMedSearch in Google Scholar
  • 3 January CT, Wann LS, Calkins H. , et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation 2019; 140 (02) e125-e151
    PubMedSearch in Google Scholar
  • 4 Konstantinides SV, Meyer G. The 2019 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2019; 40 (42) 3453-3455
    CrossrefPubMedSearch in Google Scholar
  • 5 Agnelli G, Buller HR, Cohen A. , et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (09) 799-808
    CrossrefPubMedSearch in Google Scholar
  • 6 Büller HR, Prins MH, Lensin AW. , et al; EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366 (14) 1287-1297
    CrossrefPubMedSearch in Google Scholar
  • 7 Schulman S, Kakkar AK, Goldhaber SZ. , et al; RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129 (07) 764-772
    CrossrefPubMedSearch in Google Scholar
  • 8 Büller HR, Décousus H, Grosso MA. , et al; Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369 (15) 1406-1415
    CrossrefPubMedSearch in Google Scholar
  • 9 Huisman MV, Barco S, Cannegieter SC. , et al. Pulmonary embolism. Nat Rev Dis Primers 2018; 4: 18028
    Search in Google Scholar
  • 10 van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 2014; 12 (03) 320-328
    CrossrefPubMedSearch in Google Scholar
  • 11 Agnelli G, Buller HR, Cohen A. , et al; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368 (08) 699-708
    CrossrefPubMedSearch in Google Scholar
  • 12 Weitz JI, Lensing AWA, Prins MH. , et al; EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 2017; 376 (13) 1211-1222
    CrossrefPubMedSearch in Google Scholar
  • 13 Huisman MV, Klok FA. Diagnostic management of acute deep vein thrombosis and pulmonary embolism. J Thromb Haemost 2013; 11 (03) 412-422
    CrossrefPubMedSearch in Google Scholar
  • 14 Klok FA, Tan M, Huisman MV. Letter by Klok et al Regarding Article, “18F-fluorodeoxyglucose positron emission tomography/computed tomography enables the detection of recurrent same-site deep vein thrombosis by illuminating recently formed, neutrophil-rich thrombus”. Circulation 2015; 131 (24) e530
    PubMedSearch in Google Scholar
  • 15 Tan M, Mol GC, van Rooden CJ. , et al. Magnetic resonance direct thrombus imaging differentiates acute recurrent ipsilateral deep vein thrombosis from residual thrombosis. Blood 2014; 124 (04) 623-627
    PubMedSearch in Google Scholar
  • 16 Schulman S, Kearon C. ; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
    CrossrefPubMedSearch in Google Scholar
  • 17 Prandoni P, Lensing AW, Piccioli A. , et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100 (10) 3484-3488
    CrossrefPubMedSearch in Google Scholar
  • 18 Young AM, Marshall A, Thirlwall J. , et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018; 36 (20) 2017-2023
    CrossrefPubMedSearch in Google Scholar
  • 19 Raskob GE, van Es N, Verhamme P. , et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378 (07) 615-624
    CrossrefPubMedSearch in Google Scholar
  • 20 Scheres L, Brekelmans M, Ageno W. , et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. BJOG 2018; 125 (12) 1581-1589
    CrossrefPubMedSearch in Google Scholar
  • 21 Beyer-Westendorf J, Michalski F, Tittl L, Hauswald-Dörschel S, Marten S. Vaginal bleeding and heavy menstrual bleeding during direct oral anti-Xa inhibitor therapy. Thromb Haemost 2016; 115 (06) 1234-1236
    Thieme ConnectPubMedSearch in Google Scholar
  • 22 Ferreira M, Barsam S, Patel JP. , et al. Heavy menstrual bleeding on rivaroxaban. Br J Haematol 2016; 173 (02) 314-315
    CrossrefPubMedSearch in Google Scholar
  • 23 Klok FA, Barco S. Optimal management of hormonal contraceptives after an episode of venous thromboembolism. Thromb Res 2019; 181 (Suppl. 01) S1-S5
    CrossrefPubMedSearch in Google Scholar
  • 24 Klok FA, Schreiber K, Stach K. , et al. Oral contraception and menstrual bleeding during treatment of venous thromboembolism: expert opinion versus current practice: Combined results of a systematic review, expert panel opinion and an international survey. Thromb Res 2017; 153: 101-107
    CrossrefPubMedSearch in Google Scholar
  • 25 Helmert S, Marten S, Mizera H. , et al. Effectiveness and safety of apixaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC registry. J Thromb Thrombolysis 2017; 44 (02) 169-178
    CrossrefPubMedSearch in Google Scholar
  • 26 Aryal MR, Gosain R, Donato A. , et al. Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world. Blood Adv 2019; 3 (15) 2381-2387
    CrossrefPubMedSearch in Google Scholar
  • 27 Jun M, Lix LM, Durand M. , et al; Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study. BMJ 2017; 359: j4323
    PubMedSearch in Google Scholar